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ABSTRACT
To identify host factors relevant for severe acute respiratory syndrome-coronavirus (SARS-CoV) replication, we performed a
small interfering RNA (siRNA) library screen targeting the human kinome. Protein kinases are key regulators of many cellular
functions, and the systematic knockdown of their expression should provide a broad perspective on factors and pathways pro-
moting or antagonizing coronavirus replication. In addition to 40 proteins that promote SARS-CoV replication, our study iden-
tified 90 factors exhibiting an antiviral effect. Pathway analysis grouped subsets of these factors in specific cellular processes,
including the innate immune response and the metabolism of complex lipids, which appear to play a role in SARS-CoV infec-
tion. Several factors were selected for in-depth validation in follow-up experiments. In cells depleted for the 2 subunit of the
coatomer protein complex (COPB2), the strongest proviral hit, we observed reduced SARS-CoV protein expression and a>2-log
reduction in virus yield. Knockdown of the COPB2-related proteins COPB1 and Golgi-specific brefeldin A-resistant guanine
nucleotide exchange factor 1 (GBF1) also suggested that COPI-coated vesicles and/or the early secretory pathway are important
for SARS-CoV replication. Depletion of the antiviral double-stranded RNA-activated protein kinase (PKR) enhanced virus repli-
cation in the primary screen, and validation experiments confirmed increased SARS-CoV protein expression and virus produc-
tion upon PKR depletion. In addition, cyclin-dependent kinase 6 (CDK6) was identified as a novel antiviral host factor in SARS-
CoV replication. The inventory of pro- and antiviral host factors and pathways described here substantiates and expands our
understanding of SARS-CoV replication andmay contribute to the identification of novel targets for antiviral therapy.
IMPORTANCE
Replication of all viruses, including SARS-CoV, depends on and is influenced by cellular pathways. Although substantial prog-
ress has beenmade in dissecting the coronavirus replicative cycle, our understanding of the host factors that stimulate (proviral
factors) or restrict (antiviral factors) infection remains far from complete. To study the role of host proteins in SARS-CoV infec-
tion, we set out to systematically identify kinase-regulated processes that influence virus replication. Protein kinases are key reg-
ulators in signal transduction, controlling a wide variety of cellular processes, andmany of them are targets of approved drugs
and other compounds. Our screen identified a variety of hits and will form the basis for more detailed follow-up studies that
should contribute to a better understanding of SARS-CoV replication and coronavirus-host interactions in general. The identi-
fied factors could be interesting targets for the development of host-directed antiviral therapy to treat infections with SARS-CoV
or other pathogenic coronaviruses.
Positive-stranded RNA (RNA) viruses interact with the in-fected host cell at many levels during their replicative cycle,
and thus far numerous host cell proteins that influence virus in-
fection have been identified (1, 2). These include, for example,
host factors recruited by the virus during the various stages of its
replicative cycle and those involved in the host’s defense against
virus infection. Such proteins may constitute interesting targets
for the development of novel antiviral strategies, as drug resistance
is less likely to develop when cellular rather than viral functions
are targeted. Antiviral drug resistance is a serious problem, partic-
ularly when combating RNA viruses, due to their high mutation
rate and potential for rapid adaptation.
Systems biology approaches have been instrumental in ad-
vancing our knowledge of the proteins and cellular pathways that
influence RNA virus infection. For example, systematic func-
tional genomics screens using small interfering RNA (siRNA) li-
braries have identified numerous host proteins with a role in the
replication of important human pathogens, like West Nile virus
(3), Dengue virus (4, 5), human immunodeficiency virus 1 (6),
hepatitis C virus (7–12), and influenza virus (8, 13, 14). For coro-
naviruses, a number of relevant host proteins have been described
already (15–17 and reviewed in references 2 and 18), but the use of
siRNA screens to systematically identify such factors has not been
reported thus far.
Coronaviruses, and some other members of the order Nidovi-
rales (19), have the largest RNA genomes known to date (25 to 34
kb) (20), and the complexity of their molecular biology clearly
distinguishes them from otherRNA virus groups. Although in-
fection with most established human coronaviruses is associated
with relatively mild respiratory symptoms (21, 22), the 2003 out-
break of severe acute respiratory syndrome (SARS) highlighted
the potential of zoonotic coronaviruses to cause lethal disease in











humans. The emergence of SARS-coronavirus (SARS-CoV),
which likely originated from bats, initiated an outbreak that af-
fected about 8,000 humans, with amortality rate of approximately
10% (23). Strikingly, a similar outbreak of coronavirus-induced
severe respiratory disease has been developing in a number of
Arab countries since April 2012, with 420 of the 1,100 con-
firmed cases having a fatal outcome by April 2015 (http://www
.who.int/). The causative agent, Middle East respiratory syn-
drome-coronavirus (MERS-CoV), was identified as a previously
unknown member of the betacoronavirus subgroup 2c (24, 25).
These recent developments stress the importance of developing
antiviral approaches to combat coronavirus infections and high-
light the relevance of the systematic dissection of coronavirus-host
interactions.
SARS-CoV RNA synthesis, like that of many RNA viruses
(26), takes place at virus-induced membrane structures (27, 28),
which in this case comprise a reticulovesicular network (RVN) of
modified endoplasmic reticulum (28; reviewed in reference 29).
The viral replication and transcription complexes (RTCs) are as-
sociated with this RVN, which is thought to create a suitable mi-
croenvironment for RNA synthesis and possibly also provides
protection against cellular antiviral activities. The biogenesis of
the RVN and the functional details of the RTC, in particular the
role of cellular factors and pathways, are far from understood.
Previous studies addressed coronavirus-induced immune re-
sponses, as well as a number of specific interactions between coro-
naviruses and the antiviral immune response (reviewed in refer-
ence 2). Several immune evasion mechanisms were attributed to
protein functions that are either conserved across CoVs or specific
for certain CoV lineages. Proteins such as nonstructural protein 1
(nsp1) (30), the nsp3 papain-like proteinase (31), the nsp16 2=-O-
methyltransferase (32), the nucleocapsid (N) protein (33), and the
products of SARS-CoV open reading frame 3b (ORF3b) and
ORF6 (34–37) have been reported to interfere with interferon
(IFN) induction and/or signaling. In addition, the SARS-CoV E
protein has been shown to manipulate the cellular stress response
in cell culture, including the unfolded protein response and apop-
tosis (38).
To gain more insight into the role of host factors in the SARS-
CoV replicative cycle, we set out to systematically identify kinase-
regulated cellular processes that influence virus replication. Pro-
tein kinases are key regulators in signal transduction and control a
wide variety of cellular processes. Thus, assessing their relevance
for virus replication can provide a broad perspective on factors
and pathways relevant for SARS-CoV replication, as illustrated by
previous studies identifying cellular kinases as host factors influ-
encing various stages of the replicative cycle of other RNA vi-
ruses (5, 10, 11, 39, 40).
In this study,we have screened an siRNA library that targets the
cellular kinome (779 genes) and identified 40 proviral and 90 an-
tiviral factors whose depletion significantly reduced or enhanced
SARS-CoV replication, respectively. Pathway analysis grouped
several subsets of hits in specific cellular pathways, suggesting that
these play an important role in the SARS-CoV-infected cell. Two
strong hits from the siRNA screen, the proviral 2 subunit of the
coatomer complex (COPB2) and the antiviral double-stranded
RNA-activated protein kinase (PKR), were selected for indepen-
dent validation and follow-up analysis, which confirmed their im-
portance for SARS-CoV replication. In addition, several other hits
from the primary screen were evaluated, and the relevance of the
antiviral factor CDK6 and the proviral factor PRKC could be
confirmed. Our data offer a glimpse into the complex interplay
between SARS-CoV and its host cell and provide a basis for in-
depth studies that will enhance our understanding of coronavirus
replication and coronavirus-host interactions.
MATERIALS AND METHODS
Cell culture, compound, viruses, and virus titration. 293/ACE2 (41) and
Vero E6 cells were cultured as described previously (42). Although 293/
ACE2 cells have been described as a human 293 cell-derived cell line (41),
our recent work established that these cells actually must have originated
from a nonhuman primate species that is closely related to the rhesus
monkeysMacaca mulatta and Papio anubis (43). Cells were infected with
SARS-CoV strain Frankfurt-1 (44) or green fluorescent protein (GFP)-
expressing recombinant SARS-CoV (Urbani strain) (45) as described pre-
viously (42). Sodium aurothiomalate (ATM; no. 157201; Sigma) was dis-
solved in phosphate-buffered saline (PBS) and stored as 100 mM stock at
20°C. Virus titrations were performed essentially as described before
(46). All work with infectious wild-type (wt) SARS-CoV and SARS-CoV-
GFP was performed inside biosafety cabinets in a biosafety level 3 facility
at Leiden University Medical Center.
siRNA library and transfection reagents. The ON-TARGETplus
SMARTpool protein kinases siRNA library that targets themRNAs of 779
genes, comprising the complete human kinome and some additional tar-
gets, was obtained fromDharmacon. Each individual siRNA SMARTpool
consisted of four siRNAs targeting the same gene. A nontargeting (scram-
bled) siRNA (no. D-001810-10; Dharmacon) served as a negative control,
and a glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-targeting
siRNA (no. D-001830-10; Dharmacon) was used to routinely monitor
transfection and knockdown efficiency. Stock solutions (2 M) of siRNA
SMARTpools were prepared by dissolving 0.5 nmol of an siRNA
SMARTpool in 250l of 1	 siRNA buffer (Dharmacon) according to the
manufacturer’s instructions. Using a 96-well pipettor (Rainin Liquidator
96), the contents of the siRNA library master plates were aliquoted into
volumes appropriate for individual screening experiments. The resulting
sets of 10 deep-well 96-well library plates (Greiner Bio-One) were stored
at80°C until further use.
siRNA library screening and validation. In each siRNA screen, 293/
ACE2 cells in 96-well plates containing 104 cells per well were trans-
fected with a 100-l mixture containing 100 nM siRNA, 0.2 g Dharma-
FECT1 (Dharmacon), Opti-MEM (Invitrogen), and antibiotic-free cell
culture medium, supplemented with 8% fetal calf serum (FCS) and 2.5
mM L-glutamine, according to Dharmacon’s instructions. Transfection
mixes were prepared in the 10 deep-well 96-well plates that together con-
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tained the complete library of 779 siRNASMARTpools (described above).
Using the contents of these library plates, we transfected 293/ACE2 cells in
black (3 wells per target) and transparent (3 wells per target) 96-well
plates. For a schematic representation of the experimental setup, see Fig. 2.
Transfection of individual siRNAs (ON-TARGETplus siRNAs; Dharma-
con) targetingCDK6 (no. LU-003240-00),MAP2K1 (no. LU-003571-00),
MAP2K3, (no. LU-003509-00), PKR (no. LU-003527-00), or siRNA
SMARTpools targeting COPB1 (no. L-017940-01) and GBF1 (no.
L-019783-00) was performed as described previously (42). Twenty-four
hours posttransfection (p.t.), the medium was replaced, and cells were
incubated for another 24 h at 37°C. At 48 h p.t., cells were infected with
SARS-CoV-GFP at an MOI of 10, and 24 h later they were fixed with 3%
paraformaldehyde (PFA) in PBS. GFP expression was quantified by mea-
suring fluorescence in a 96-well plate reader (Berthold Mithras LB 940)
using excitation and emission wavelengths of 485 and 535 nm, respec-
tively. The fluorescence in wells containing mock-infected cells was used
to correct for background signal.
GAPDH and cell viability assays. At 48 h p.t., GAPDH enzyme activ-
ity in lysates of siRNA-transfected cells was measured using the KDalert
GAPDHassay kit (Ambion) according to themanufacturer’s instructions.
Possible cytotoxic effects of siRNA transfection were analyzed (in tripli-
cate) at 48 h p.t., using the CellTiter 96 AQueous non-radioactive cell pro-
liferation assay (Promega). After 90 min, the reaction was terminated by
the addition of 25 l of 10% SDS, and absorbance at 490 nm (A490) was
measured using a 96-well plate reader (Berthold).
Data analysis.Rawdata fromGFP fluorescence and cell viabilitymea-
surements were analyzed per individual screen with the Bioconductor/R
package CellHTS2 (47) withminormodifications (see Results for details).
Average GFP expression (n 
 3) and cell viability were calculated and
normalized to the signals of scrambled siRNA-transfected (control) cells.
A two-sided one-sample Student’s t test was used on the log2-transformed
normalized values to determine the significance (P 0.05) of the changes
in GFP expression caused by siRNA transfection. The siRNA transfection
was considered noncytotoxic when the normalized cell viability assay
readings (A490) were above 0.85 (P 0.05). Significance was determined
using a one-sided one-sample Student’s t test on the log2-transformed
normalized values using  0.85 as the null hypothesis.
Gene silencing using lentivirus-expressed shRNAs. Vectors for ex-
pression of short hairpin RNAs (shRNAs) targeting human COPB2 (no.
TRCN-065114; accession no. NM_004766) or expression of a nontarget-
ing (scrambled) control shRNA (no. SHC-002) were picked from the
Mission TRC-1 library of shRNA-expressing lentiviruses (Sigma), and
lentivirus stocks were prepared according to the manufacturer’s instruc-
tions. Lentivirus particle titers were determined using a p24 enzyme-
linked immunosorbent assay (ELISA) (Zeptometrix) according to the
manufacturer’s instructions. Wells (4 cm2) containing 8	 104 293/ACE2
cells were transduced with shRNA-expressing lentiviruses at an MOI of 3
in culture medium containing 8 g/ml Polybrene, and after 24 h fresh
medium was given. At 72 h p.t., cells were infected with wt SARS-CoV or
SARS-CoV-GFP (MOI, 0.01), and depletion of COPB2 was validated by
Western blotting.
Protein analysis and antibodies. Total cell lysates were prepared in
4	 Laemmli sample buffer (100 mMTris-HCl, pH 6.8, 40% glycerol, 8%
sodium dodecyl sulfate [SDS], 40 mM DTT, 0.04 mg/ml bromophenol
blue), after which samples were heated at 95°C for 15 min. Following
SDS-PAGE, proteins were transferred to Hybond-LFP membranes (GE
Healthcare) by semidry blotting, and membranes were blocked with 1%
casein in PBS containing 0.1% Tween 20 (PBST). The following antisera
against cellular proteins were used: rabbit anti-PKR (no. 610764; BD Bio-
sciences), goat anti-COPB2 (sc-13332; Santa-Cruz), rabbit anti-CDK6
(sc-177; Santa Cruz), rabbit anti-MAP2K1 (710446; Life Technologies),
rabbit anti-MAP2K3 (sc-961; Santa Cruz), and mouse monoclonal anti-
bodies against -actin (A5316; Sigma) and the transferrin receptor (TfR;
no. 13-6890; Invitrogen). Rabbit antisera against SARS-CoV nsp8 and N
protein (28, 48) were used to analyze viral protein expression. After over-
night incubation with the primary antibody, membranes were probed
with biotinylated secondary antibodies (rabbit anti-goat, swine anti-rab-
bit, or goat anti-mouse) for 1 h at RT, after which a tertiary mouse anti-
biotin-Cy3 antibody was used to visualize protein bands using a Typhoon
9410 scanner (GE Healthcare).
Canonical pathway analysis. The Ingenuity Pathway Analysis (IPA)
package was used to assign hits to canonical cellular pathways. The signif-
icance of the association between the data set and the respective pathways
was determined in twoways: (i) the number ofmolecules from the data set
that mapped to a specific pathway divided by the total number of mole-
cules in that canonical pathway (the higher the percentage of hits identi-
fied in a specific pathway, the higher the likelihood it plays a role in the
viral replicative cycle); (ii) Fisher’s exact test was used to determine the
probability that the association between the genes in the data set and
the canonical pathway is explained by chance alone.
RESULTS
Development of an siRNA screening protocol for host factors
involved in nidovirus replication. A robust protocol was devel-
oped to assess the effect of systematic knockdown of individual
host kinases on the replicative cycle of SARS-CoV (this study) and
the distantly related arterivirus equine arteritis virus (EAV; K. F.
Wannee, A. H. de Wilde, C. Beugeling, P. ten Dijke, E. J. Snijder,
M. J. van Hemert, and M. Kikkert, unpublished data), which was
applied to the screening of a commercial human kinome-directed
siRNA library (779 targets). We performed our siRNA screens in
293/ACE2 cells (41), which express the SARS-CoV receptor ang-
iotensin-converting enzyme 2 and, in contrast to other cell lines
tested, were found to be permissive to a combination of siRNA
transfection and infection with either SARS-CoV or EAV. This
property facilitated direct comparative studies between these two
distantly related nidoviruses. Unfortunately, after completion of
the siRNA screens, it was discovered that these cells are not of
human origin but most likely have originated from an OldWorld
monkey closely related to Papio anubis andMacaca mulatta (43).
Nevertheless, because the sequence identity between the human
genome and that of several Old World monkeys is 94% (49) and
because pools of four siRNAs were used for each target, we believe
that the consequences of the misidentification of this cell line are
limited, although the chance of false-negative hits may have been
somewhat increased (49). Infection of 293/ACE2 cells with SARS-
CoV-GFP at an MOI of 10 yielded a robust and readily detectable
GFP signal at 24 h p.i. (Fig. 1A). The GFP signal was stronger at 28
and 30 h p.i., indicating that it had not yet reached a plateau at 24
h p.i. (Fig. 1A). Therefore, we chose the latter time point to fix cells
and measure GFP fluorescence, as it also should allow the identi-
fication of antiviral factors whose knockdown would increase re-
porter gene expression. The 293/ACE2 cells could be efficiently
transfected with siRNAs, as illustrated by a consistent 75% re-
duction of GAPDH activity at 48 h p.t. using an siRNA SMARTpool
targeting the GAPDH mRNA (Fig. 1B, white bars). No change in
cell viability was detected by 48 h p.t. following transfection with
either a scrambled siRNA or the GAPDH-specific siRNA (Fig. 1B,
gray bars). When these cells subsequently were infected with
SARS-CoV-GFP (MOI, 10), no significant differences in GFP ex-
pression were observed at 24 h p.i. compared to control cells that
had not been transfected with siRNAs. This demonstrated that the
siRNA transfection procedure per se did not adversely affect
SARS-CoV-GFP replication (Fig. 1B, black bars).
Kinome-wide siRNA screens for host factors involved in
SARS-CoV replication. A human kinome-directed siRNA screen
de Wilde et al.











was performed to identify host cell kinases that affect SARS-CoV-
GFP replication according to the experimental set-up outlined in
Fig. 2. For each independent siRNA screening experiment, we
used a set of ten 96-well library plates, each containing approxi-
mately 80 specific siRNA SMARTpools and several controls.
Transfection mixes (final concentration of 100 nM siRNA) were
prepared in these library plates and their contents was used to
transfect (per library plate) 293/ACE2 cells in three black and
three transparent 96-well plates. Forty-eight hours after siRNA
transfection, the black plates were infected with the SARS-CoV-
GFP reporter virus (MOI, 10), and at 24 h p.i. GFP expression was
measured by fluorometry. At the moment of infection, the trans-
parent plates were used to monitor (potential) cytotoxic effects of
siRNA transfection using a colorimetric cell viability assay. The
complete siRNA screen, i.e., the viability controls (in triplicate for
each siRNA SMARTpool) and the quantitation of SARS-CoV-
driven GFP expression (in triplicate), was repeated in three inde-
pendent experiments. The data, obtained from a 96-well plate
reader, was processedwith the Bioconductor/R packageCellHTS2
as described previously (47). Experimental controls were as-
signed, and the NPI method (normalized percent of inhibition)
was used to normalize GFP fluorescence values to those of scram-
bled siRNA-transfected cells and to correct for plate-to-plate
variation. Subsequently, the GFP data were transformed to amul-
tiplicative scale (the value obtained using scrambled siRNA-trans-
fected cells was set to 1). The results for each replicate library
screen next were summarized and used for further data analysis,
including the assignment of gene identifiers to each well. Finally,
FIG 1 Viability and susceptibility to SARS-CoV infection of siRNA-trans-
fected 293/ACE2 cells. (A) 293/ACE2 cells were infected with SARS-CoV-GFP
(MOI, 10), and at 24, 28, and 30 h p.i., cells were fixed and GFP fluorescence
was measured. (B) 293/ACE2 cells were transfected with siRNAs targeting
GAPDH mRNA or a scrambled control siRNA (Scr). At 48 h p.t., cells were
infected with SARS-CoV-GFP (MOI, 10), and 24 h later cells were fixed and
GFP expression was measured (black bars). Cell viability (dark gray bars) was
analyzed at 48 h after siRNA transfection, and knockdown of GADPH expres-
sion was monitored by measuring enzymatic activity (light gray bars). All
values were normalized to those obtained with nontransfected control cells
(100%).
FIG 2 Design of siRNA library screening procedure. See the text for details.
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the data from the three independent library screens were com-
bined and summarized.
Host cell kinases were considered to have a proviral effect when
their siRNA-mediated knockdown reduced the GFP signal (neg-
ative score values), and kinases were considered antiviral when the
GFP signal increased upon their knockdown (positive score val-
ues). Graphical representations of the hit distribution per plate
were visually inspected in order to minimize the chance of false-
positive or false-negative hits due to major (technical) artifacts
(data not shown).
Using scrambled siRNA-transfected control cells as a refer-
ence, the knockdown of most cellular kinases was found to be
noncytotoxic within the time frame of this experiment (Fig. 3A;
also see Data Set S1 in the supplemental material). Transfection of
siRNAs was considered to be cytotoxic when the viability of cells
transfected with a target-specific siRNA pool was 85% of the
viability of control cells transfected with scrambled siRNAs (Fig.
3A). Using this criterion, 222 out of 779 (28.5%) transfections
with the specific siRNA pools appeared to be toxic to the cells. A
minor fraction (50 targets; 6.4%) appeared to be highly detrimen-
tal (normalized viability value below 75%). To prevent false-pos-
itive proviral hits due to a general negative effect on cell viability or
cell division, we excluded all targets whose knockdown was asso-
ciated with viability measurements below 85%. Such data filtering
was not applied for antiviral hits (i.e., hits whose knockdown en-
hanced GFP expression), since siRNA-induced cytotoxicity is ex-
pected to inhibit virus replication and should not give rise to false-
positive antiviral hits.
Proviral and antiviral proteins and pathways in SARS-CoV-
GFP infection. After exclusion of cytotoxic siRNA SMARTpools
that decreased GFP expression (described above), the remaining
684 targets were ranked on the basis of the GFP signal in host
factor-depleted SARS-CoV-GFP-infected cells compared to con-
trol cells (Fig. 3B). Targets were qualified as antiviral or proviral
hits if GFP expression differed significantly from that in infected
control cells transfected with the scrambled siRNA pool (P 
0.05). Knockdown of themajority of the targets (552 proteins) did
not significantly alter GFP reporter gene expression (P  0.05).
However, as is not uncommon in this type of screening experi-
ment and considering the issue with the origin of the cell line used
(described above), we cannot formally exclude that our results
were influenced to some extent by insufficient knockdown of cer-
tain target genes by the siRNA pools in the library.
Using the criteria outlined above, a total of 90 cellular proteins
(19.4%of all targets)were identified as antiviral factors, since their
depletion significantly increased GFP expression, although for
most of them it did so less than 2-fold. The 10 best antiviral hits are
depicted in Fig. 4A (the complete data set is provided in Data Set
S1 in the supplementalmaterial). Forty proviral factors were iden-
tified, and the knockdown of nine of those reduced GFP expres-
sion by more than 2-fold (Fig. 4B) (for the complete data set, see
Data Set S1). Although according to the criteria formulated above
(P  0.05), ANGPT4 (214%; P 
 0.0555) and PKR (210%; P 

0.0884) formally did not qualify as antiviral hits, we have included
these proteins in view of the exceptionally strong stimulation of
GFP expression triggered by their knockdown (Fig. 4A). Further-
more, since its knockdown resulted in an almost 3-fold decrease of
the GFP signal (35%; P
 0.0004), DGKE was included as a pro-
viral hit, despite the fact that the viability assay did not rigorously
FIG 3 Results of the siRNA screens for host factors influencing SARS-CoV
replication. (A) Viability assays were done at 48 h p.t., and data were normal-
ized to the measurements for control cells transfected with scrambled siRNA
(100%). Data were binned into 4 viability categories, as indicated below the x
axis, and the number in each bar is the absolute number of siRNA targets
within that category. The fraction of the total number of targets (779) in each
category is indicated above each bar. For each siRNA pool in the library, the
viability data are the averages from nine measurements, resulting from three
independent library screens. (B) The plot shows the distribution of the log2-
transformed values of GFP reporter gene expression by SARS-CoV-GFP in
siRNA-transfected cells, normalized to the GFP signal of infected control cells
that were transfected with scrambled siRNA. Targets were ranked based on the
magnitude of the effect of their knockdown on SARS-CoV replication. Targets
were considered to have a robust antiviral effect when their knockdown in-
creased reporter gene expression to at least 150% (red area above the x axis).
Proviral hits, whose knockdown induced an at least 2-fold reduction in GFP
expression, are depicted in the green area below the x axis. Proviral targets
whose knockdown reduced cell viability to below 85% were excluded (see
main text), leaving a total of 684 targets included in the final analysis. The plot
represents the averages from three library screens (each done in triplicate).
de Wilde et al.











exclude cytotoxic effects for this siRNA pool (viability, 88%; P

0.0540).
The pro- and antiviral hits identified in the siRNA screen were
mapped to cellular pathways using the IPA software package. Fig-
ure 5 shows the canonical pathways and more general functional
categories (highlighted in color) in which the proviral (green) and
antiviral (red) hits were strongly represented (P  0.05). These
pathways included apoptosis, cellular immune response, growth
factor signaling, cellular homeostasis, metabolism of complex lip-
ids, and intracellular and second messenger signaling.
Evaluation of antiviral hits.An unexpectedly large number of
antiviral hits was identified in the primary siRNA screen, although
formost of themknockdown resulted in a less than 2-fold increase
in SARS-CoV-drivenGFP expression. To assess the overall quality
of our siRNA screen and the reliability of the identification of
antiviral hits in particular, we selected a set of strong and weak
antiviral hits for further evaluation, namely, PKR, ANGPT4,
CLK1 (2-fold increase inGFP signal), CDK6 (1.8-fold increase),
MAP2K3 (1.6-fold increase), and MAP2K1 (1.2-fold increase).
Per target, a deconvoluted set of four individual siRNAs was used
for additional knockdown experiments, after which SARS-CoV-
GFP replication was quantified, and then the knockdown effi-
ciency at the protein level for each target was evaluated byWestern
blotting (Fig. 6). We checked whether there was strong similarity
between the target sequence of our (human) siRNAs and the cor-
responding Macaca mulatta sequence, considering the origin of
the 293/ACE2 cells (described above). This was the case for all
siRNAs except for siRNA CDK6 number 4, which was excluded
from further analysis. Using commercially available antisera
against the human proteins, we were unable to reliably detect en-
dogenous expression of ANGPT4 and CLK1. Therefore, it re-
mains uncertain whether ANGPT4 and CLK1 are true antiviral or
false-positive hits, as we could not determine knockdown levels
and correlate these to effects on virus replication (data not
shown).
The mitogen-activated protein kinases (MAPKs) were rela-
tively highly represented among the antiviral hits (Fig. 5; also see
Data Set S1 in the supplemental material); therefore, we included
MAP2K1 and MAP2K3 in our secondary evaluation. MAP2K1
was a weak antiviral hit in the primary screen, as its depletion led
to an 1.2-fold increased GFP expression. In validation experi-
ments with individual siRNAs, we also observed a small but non-
significant increase in SARS-CoV-driven GFP expression (Fig.
6A). Western blot analysis of siRNA-transfected cells that were
infected with wt SARS-CoV revealed poor knockdown efficien-
cies, and a clear correlation between the level of MAP2K1 and
SARS-CoV N protein expression could not be established (Fig.
6B). The siRNA that gave the best knockdown ofMAP2K1 (num-
ber 2) had no effect on GFP expression, suggesting that this weak
antiviral hit was a false positive in the primary screen. Knockdown
of MAP2K3 resulted in a 1.6-fold increased SARS-CoV-driven
GFP expression in the primary screen (see Data Set S1). In cells
transfectedwith a deconvoluted set of individual siRNAs targeting
the MAP2K3 mRNA, we observed a significant increase in GFP
expression for 3 out of 4 siRNAs (Fig. 6C). However, in siRNA-
transfected cells that were infected with wt SARS-CoV, only the in-
FIG 4 Heat maps of pro- and antiviral hits identified in this study. (A) List of the 10 most prominent antiviral (A) and proviral (B) hits. For each target, the P
value, accession number, and gene name are shown. Each data point represents the result of a single library screen and is the average from 3 replicates that were
done in each screen. The full hit lists can be found in Data Set S1 in the supplemental material.
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troduction of siRNAnumber 3 led to clearly enhanced SARS-CoVN
protein expression (Fig. 6D). The other siRNAs actually reduced ex-
pression of N protein, with an apparent correlation between the re-
maining percentage ofMAP2K3 andNprotein levels. Based on these
results, MAP2K3 could not be confirmed as an antiviral hit.
Wewere able to detect expression of cyclin-dependent kinase 6
(CDK6; 1.8-fold increase in GFP expression in the primary
screen) and found that CDK6 siRNA numbers 1 and 2 reduced
protein levels by at least two-thirds (Fig. 6F). Transfection with
the same siRNAs significantly enhanced SARS-CoV-GFP replica-
tion (Fig. 6E), and in cells infected with wt SARS-CoV, this led to
an 1.5- to 2-fold increase in N protein levels (Fig. 6F). These
FIG 5 Cellular pathways influencing SARS-CoV-GFP replication. Graphical representation of the canonical pathways (white ellipses) identified in the siRNA
library screen for cellular factors affecting SARS-CoV replication. All proviral (green) and antiviral (red) hits (for a complete list, see Data Set S1 in the
supplementalmaterial) for which depletion significantly altered SARS-CoV-GFP replicationwere used to identify cellular pathways by IPA inwhich the hits were
clearly overrepresented, and only those pathways and the hits represented in them are shown here. The hits are represented by nodes with lines linking them to
one or more canonical pathways. The color intensity of the nodes indicates the strength of the pro- or antiviral effect (log2 ratio of GFP expression normalized
to infected control cells), e.g., factors with a stronger antiviral effect have a more intense red color. The identified canonical pathways were clustered into more
general categories that are indicated by text boxes in the colored background shading.
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results suggest CDK6 is a bona fide antiviral hit, as its depletion
leads to a moderate but significant and reproducible increase in
SARS-CoV replication.
Taken together, the results of our validation experiments sug-
gest that the antiviral hits identified in the primary screen should
be considered with caution, as several of themmay have been false
positives, especially those that had a moderate (but significant)
effect in the primary screen.
Validation of PKR as an antiviral factor in SARS-CoV repli-
cation. PKR was one of the strongest of the 90 antiviral hits that
were identified in the primary siRNA library screen. In two inde-
pendent follow-up experiments with reordered PKR-specific
siRNA SMARTpools, a more than 2-fold increase in GFP expres-
sion by SARS-CoV-GFP was observed (data not shown), suggest-
ing that PKR is a bona fide antiviral hit. PKR is a serine/threonine
protein kinase that is activated by double-stranded RNA
(dsRNA), a hallmark of RNA virus infection, and the activated
form of PKR blocks translation initiation through eIF-2 phos-
phorylation (reviewed in reference 50).
To further validate the antiviral role of PKR in SARS-CoV rep-
lication, a deconvoluted set of four single PKR-directed siRNAs
was used, and transfection of 293/ACE2 cells with three of these
siRNAs (numbers 2, 3, and 4) significantly increased SARS-CoV-
driven GFP expression (Fig. 7A, black bars). Cell viability was
slightly reduced after transfection with these PKR-directed siRNAs,
in particular using siRNA number 2, which caused a 14% reduc-
tion in cell viability (Fig. 7A, gray bars). Nevertheless, despite the
fact that this siRNA adversely affected cell viability, an increase
rather than a decrease of SARS-CoV-driven GFP expression was
observed.
Transfection with PKR-specific siRNAs reduced PKR levels in
293/ACE2 cells up to 87% compared to control cells, depending
on the siRNA used (Fig. 7B). To verify that PKR knockdown in-
creased wt SARS-CoV replication, siRNA-transfected 293/ACE2
cells were infectedwithwt SARS-CoV and viral protein expression
was analyzed by Western blotting. In line with the effect of PKR
siRNA number 2 on 293/ACE2 cell viability (Fig. 7A), cells trans-
fected with this siRNA contained reduced levels of -actin, which
FIG 6 Evaluation of the antiviral hits CDK6, MAP2K1, andMAP2K3. 293/ACE2 cells were transfected with four individual siRNAs targeting, MAP2K1 (A and
B), or MAP2K3 (C and D) or three CDK6-specific siRNAs (E and F). A nontargeting scrambled siRNAwas used as a control. At 48 h p.t. cells were infected with
SARS-CoV-GFP at an MOI of 10 (A, C, and E) and fixed 24 h later, and GFP fluorescence (black bars) was quantified and normalized to the value measured in
infected, scrambled siRNA-transfected cells (100%). The effect of siRNA transfection on cell viability was analyzed in parallel (gray bars), and values were
normalized to those of scrambled siRNA-transfected control cells (100%). Each experiment was repeated at least three times (averages standard deviations
[SD]). In parallel, siRNA-transfected cells were infectedwithwt SARS-CoV (MOI, 5), and at 8 h p.i., SARS-CoVNexpressionwasmonitored byWestern blotting
(B, D, and F). TfR was used as a loading control. Knockdown levels of the host proteins were analyzed by Western blotting (B, D, and F). The amount of
SARS-CoV N protein and remaining quantity of host protein compared to that of scrambled siRNA-transfected cells (100%) is shown below each lane. All
experiments were repeated at least twice.
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was used as loading control (Fig. 7C, lower). Transfection with
two of the four individual PKR-directed siRNAs (2 and 3) clearly
increased the expression of SARS-CoVN protein (Fig. 7C, upper)
and also led to an1-log increase in infectious progeny titers (Fig.
7D). Taken together, the increases in GFP signal, N expression,
and infectious progeny titer correlate well with the magnitude of
PKR knockdown, which confirms a strong antiviral role for PKR
in SARS-CoV-infected cells.
Confirmation of a proviral role for protein kinase C iota in
SARS-CoV replication. For the evaluation of the proviral hits of
the primary screen (Fig. 4B), four hits were selected that caused
either a 5-fold reduction (COPB2 and CDK5R2) or a more mod-
erate 2-fold reduction in SARS-CoV-driven GFP expression
(IHPK1 and PRKC). We were unable to detect endogenous
CDK5R2 and IHPK1 byWestern blotting; therefore, we could not
validate the proviral role of these two host factors (data not
shown). The proviral role of PRKC and COPB2 could be vali-
dated as discussed in the sections below.
The proviral effect of protein kinase C iota (PRKC) was vali-
dated using the chemical inhibitor sodium aurothiomalate
(ATM), which blocks the interaction between PRKC and other
PB1 domain-containing proteins (51, 52). VeroE6 and 293/ACE2
cells infected with SARS-CoV-GFP were treated with 0.13 to 20
M ATM, starting 2 h prior to infection. In both 293/ACE2 (Fig.
8A) and in VeroE6 cells (Fig. 8B), SARS-CoV-mediated GFP ex-
pression was efficiently inhibited by ATM in a dose-dependent
manner, with 50% effective concentrations (EC50s) of 0.58 and
1.06 M, respectively. No cytotoxicity was observed at the ATM
concentrations used (Fig. 8).
COPB2 and proteins of the early secretory pathway are im-
portant for SARS-CoV replication. COPB2 (or =-COP) was
identified as the strongest proviral hit in our screen, as its knock-
down resulted in an 82% decrease of GFP expression (Fig. 4B).
The coatomer protein complex, of which COPB2 is a subunit,
contains a total of seven protein subunits (-, -, =-, -, -, ε-,
and -COP) and drives the formation of COPI-coated vesicles,
which function in retrograde transport in the early secretory path-
way (53). To validate its role as a proviral host factor in SARS-CoV
replication, COPB2 was depleted by transducing 293/ACE2 cells
with lentiviruses expressingCOPB2mRNA-specific shRNAs. This
reduced COPB2 levels by 70% compared to levels of control
cells transduced with a lentivirus expressing a scrambled shRNA
(Fig. 9A), a reduction that did not affect cell viability (Fig. 9B).
Subsequent infection of COPB2-depleted cells with SARS-CoV-
GFP resulted in a strong decrease ofNprotein andGFP expression
(Fig. 9C, left). To exclude that the observed effect was an artifact
caused by the use of the GFP reporter virus, we also analyzed viral
protein expression and virus yield in COPB2-depleted cells in-
fected with wt SARS-CoV. As for SARS-CoV-GFP, a clear reduc-
tion in N protein expression then also was observed in COPB2-
depleted cells compared to the level in cells transduced with a
FIG 7 Validation of PKR as an antiviral factor in SARS-CoV replication.
293/ACE2 cells were transfected with four individual siRNAs targeting PKR or
a scrambled control siRNA. (A) At 48 h p.t. cells were infected with SARS-
CoV-GFP (MOI, 10) and fixed 24 later, and GFP fluorescence (black bars) was
quantified and normalized to the value measured in infected, scrambled
siRNA-transfected cells (100%). The effect of siRNA transfection on cell via-
bility was analyzed in parallel (gray bars), and values were normalized to those
of scrambled siRNA-transfected control cells (100%). Averages SD are given
(***,P 0.001). (B) Knockdownof PKR expression at 48 h p.t. wasmonitored
byWestern blotting, and the percentage of PKR remaining compared to that of
scrambled siRNA-transfected cells is shown below each lane. TfR was used as a
loading control. (C) Cells transfected with PKR-specific siRNAs and control
cells were infected with SARS-CoV (MOI, 0.01), and 24 h later these cells were
lysed to assess SARS-CoV N levels by Western blotting (shown below the
panels as a percentage of the control), using-actin as the loading control. (D)
Virus titers in the 24-h p.i. culture supernatants of wt SARS-CoV-infected cells
(MOI of 0.01) transfected with PKR-specific or scrambled siRNA. All experi-
ments were repeated at least twice.
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lentivirus expressing a scrambled shRNA (Fig. 9C, right). Titra-
tion of culture supernatants from SARS-CoV-GFP-infected cells
and wt SARS-CoV-infected cells revealed a 2- to 3-log reduction
for both viruses upon COPB2 depletion (Fig. 9D).
To further substantiate the importance of COPI-coated vesi-
cles for SARS-CoV replication, another component of the
coatomer protein complex, subunit 1 (COPB1), was depleted by
transfection of 293/ACE2 cells with a COPB1 mRNA-specific
siRNA SMARTpool. Depletion of COPB1 resulted in an 83% re-
duction of SARS-CoV-driven GFP expression (Fig. 9E). The for-
mation of COPI-coated vesicles is mediated through activation of
ADP ribosylation factor 1 (Arf1) by Golgi-specific brefeldin A-re-
sistant guanine nucleotide exchange factor 1 (GBF1) (54). There-
fore, we also analyzed the importance of GBF1. GFP reporter gene
expression by SARS-CoV-GFP was reduced by 89% in 293/ACE2
cells that had been depleted for GBF1 (Fig. 9E). GBF1 and COPB1
depletion had no significant effect on cell viability (Fig. 9E). Taken
together, these data suggest that COPB2 andCOPI-coated vesicles
play an essential role in SARS-CoV replication.
DISCUSSION
In the past decade, functional genomics studies have systemati-
cally identified host factors that can influence the replication of
diverse RNA viruses (3, 4, 8–10, 39, 55). Here, we describe a
human kinome-wide siRNA screen that aimed to identify factors
influencing the entry and replication of SARS-CoV. To our
knowledge, this is the first report on a systematic functional
genomics study of this kind for any coronavirus. As kinases are key
regulators of many cellular processes, the pro- and antiviral fac-
tors identified in this study should pinpoint cellular pathways that
are important for SARS-CoV replication.
After we had completed our screen, we unfortunately discov-
ered that the 293/ACE2 cells used were not of human origin but
must have derived from a nonhuman primate, probably an Old
World monkey closely related to Macaca mulatta. This may have
increased the number of false-negative hits due to mismatches
between siRNAs designed to target human genes and the sequence
of the homologous monkey mRNAs. However, the human and
Macacamulatta genomes are 94% identical, and even a nucleotide
mismatch in an siRNAwould not automatically render it inactive,
as it might still silence gene expression by blocking translation of
the mRNA (56). Therefore, we concluded that, despite this post-
screening complication, we should still be able to identify host
factors that are relevant for coronavirus infection. Moreover, it is
important to stress that the use of a nonhuman primate cell line
should not have increased the number of false-positive hits. The
cell line was highly susceptible to both SARS-CoV and EAV infec-
tion and could be efficiently transfectedwith siRNAs. This allowed
us to perform siRNA screens for host factors involved in the rep-
lication of these two distantly related nidoviruses and to directly
compare hits (Wannee et al., unpublished).
A recombinant SARS-CoV-GFP reporter virus, in which
ORF7a andORF7bwere replaced by theGFP gene,was used in our
screen in order to conveniently quantify the effect of gene knock-
down on virus replication. The SARS-CoV ORF7a protein is
known to interact with the structural envelope (E), membrane
(M), and spike (S) proteins (57), and some studies suggest that it is
involved in specific virus-host interactions (35, 58, 59). However,
the replication efficiency in cell culture of SARS-CoV mutants
lacking both ORF7a and ORF7b is unchanged (60, 61), and there
were none of the differences in replication kinetics, morbidity,
and mortality observed in a hamster infection model (61). Al-
though the deletion of the two accessory protein genes likely has
affected the results of our primary screen only marginally, a wt
SARS-CoV isolate was used in several of the validation experi-
ments to rule out artifacts caused by the lack of expression of
ORF7a and ORF7b. In all cases tested, we did not find major
differences between wild-type virus and the deletion mutant.
For SARS-CoV, screening of the kinome-directed library of
779 siRNA SMARTpools resulted in the identification of 90 anti-
viral and 40 proviral proteins. Canonical cellular processes and
pathways in which these factors were represented strongly include
inositol phosphate metabolism, signaling by Rho family GTPases,
and stress-activated protein kinase/JunN-terminal protein kinase
(SAPK/JNK) signaling (Fig. 5). Many of the hits also could be
mapped to the interleukin-2 (IL-2), IL-6, IL-8, and IL-17 signaling
pathways, which have been implicated previously in controlling
coronavirus infection and coronavirus-induced inflammation
(reviewed in reference 2). For example, the SARS-CoV spike (S)
protein was shown to induce the expression of the proinflamma-
FIG 8 Validation of PRKC as proviral host factor. 293/ACE2 (A) or VeroE6 (B) cells in 96-well plates were infected with SARS-CoV-GFP (MOI, 10). Treatment
with 0.13 to 20 M sodium aurothiomalate (ATM) was started 2 h prior to infection, and cells were fixed at 18 h p.i. (VeroE6) or 24 h p.i. (293/ACE2). GFP
reporter gene expression (black bars) wasmeasured and normalized to the signal in untreated control cells (100%). The gray lines show the effect of ATMon the
viability of mock-infected cells normalized to the viability of solvent-treated control cells. Graphs show the results (averages and SD) from a representative
experiment performed in quadruplicate. Both experiments were repeated at least twice.
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tory cytokine IL-8 (62), and IL-6 and IL-8 levels were elevated in
the serum of SARS-CoV-infected patients (62, 63). Furthermore,
mouse hepatitis virus (MHV) and infectious bronchitis virus
(IBV) infections were reported to upregulate the synthesis of these
same cytokines (64, 65). Although our siRNA library screen did
not target interleukins directly, the identification of (kinase-regu-
lated) interleukin signaling pathways is in line with these earlier
studies and emphasizes their importance in SARS-CoV infection.
A list of host proteins involved in SARS-CoV infection is no
more than a good starting point for follow-up studies into the role
of individual host protein or pathways in the virus replication
cycle. Previous studies on other viruses, e.g., HIV-1, showed a very
limited overlap between hits from independent siRNA screens
performed in different laboratories (66), highlighting the impor-
tance of validation and follow-up studies. To judge the overall
quality of our siRNA screen, six hits with various impacts on
SARS-CoV-driven GFP expression were chosen for validation.
Four of these, PKR,CDK6, COPB2, and PRKC (Fig. 6 to 9), could
be confirmed. The weak antiviral hits MAP2K1 and MAP2K3
could not be confirmed, as in follow-up experiments knockdown
could not be achieved or did not convincingly affect SARS-CoV
replication, respectively. Interestingly, the diacylglycerol kinase
was highly represented as hits in the primary screen (6 of 8 targets;
see Data Set S1 in the supplemental material). Although not in-
cluded in follow-up experiments presented here, a related study
that aimed to identify host factors with a general effect in nidovi-
rus infection (Fig. 4 and Wannee et al., unpublished) confirmed
that one of these hits, diacylglycerol kinase epsilon (DGKE), plays
a role in the SARS-CoV replication cycle.
MAP2K3, a kinase that acts in the p38 MAPK module, was a
moderate hit in our primary screen. This MAP kinase signaling
pathway is involved in multiple processes, like regulation of in-
flammatory responses, cell proliferation, and cell cycle progres-
sion (reviewed in reference 67). This pathway has been implicated
in the replication of other coronaviruses, but its exact role still is
not fully understood. Activation of p38 MAPK promotes MHV
replication (65), and chemical inhibition of the p38 MAPK path-
way restricts HCoV-229E replication (68). Overexpression of the
SARS-CoVORF3a (69) andORF7a (35) proteins activates the p38
MAPK signaling pathway, but the role of this pathway in SARS-
FIG 9 Proteins of the early secretory pathway are important for SARS-CoV replication. (A) 293/ACE2 cells were transduced with lentiviruses expressing a
COPB2 mRNA-specific or a scrambled shRNA. Knockdown of COPB2 expression at 48 h p.t. was monitored by Western blotting with a COPB2-specific
antiserum, and cyclophilin B (CypB) was used as a loading control. (B) Viability of COPB2-depleted 293/ACE2 cells was analyzed at 48 h after transduction
(percentage of control cells transduced with lentiviruses expressing a scrambled shRNA). (C and D) COPB2-depleted and control cells were infected with either
SARS-CoV-GFP or wt SARS-CoV (MOI of 0.01). (C) SARS-CoV protein expression at 32 h p.i. (SARS-CoV-GFP) or 24 h p.i. (wt SARS-CoV) was analyzed by
Western blotting with N-specific and GFP-specific antisera, using the TfR protein as a loading control. SARS-CoV N protein expression was quantified and
normalized to that in scrambled siRNA-transfected cells (100%) as indicated under each lane. (D) SARS-CoV-GFP (white bars) and wt SARS-CoV (black bars)
progeny titers in the culture supernatants of control or COPB2-depleted cells at 32 h p.i. (SARS-CoV-GFP) or 24 h p.i. (wt SARS-CoV). (E) Normalized GFP
expression by SARS-CoV-GFP in 293/ACE2 cells transfected with siRNA SMARTpools targeting COPB1, GBF1, or a scrambled control siRNA. Cells were
infected 48 h p.t. at an MOI of 10, and 24 h later GFP fluorescence was quantified and normalized to that in infected cells transfected with a scrambled siRNA.
GFP fluorescence data are the averages from three independent experiments.
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CoV-infected cells remains unclear. Our screen identified several
proteins fromMAPK signaling cascades, but our validation stud-
ies suggested that MAP2K3 was a false-positive hit. This is sup-
ported by the fact that the inhibitor SB203580 had no effect on
SARS-CoV replication in cell culture (data not shown). This com-
pound was previously shown to block HCoV-229E infection in
cell culture (68) and to increase the survival of SARS-CoV-in-
fected mice through reducing the SARS-CoV-induced inflamma-
tory response (70).
CDK6, a kinase involved in cell cycle progression from G1 to S
phase (71), was confirmed as an antiviral hit. Depletion of CDK6
results in G1 phase cell cycle arrest. In addition, CDK6 also is
involved in NF-B signaling and coregulation of inflammatory
genes by binding and activation of the p65 subunit of NF-B (72,
73). Consequently, besides the effect on the cell cycle, depletion of
CDK6 also might reduce the inflammatory response against virus
infection. A recent study by DeDiego et al. highlighted the rele-
vance of NF-B-mediated inflammation in SARS-CoV-infected
mice (74). Several laboratories studied the (antiviral) role of
CDK6, and cell cycle progression in general, in coronavirus repli-
cation. For MHV, it has been shown that upon high-MOI inocu-
lation, the virus induces cell cycle arrest in the G0/G1 phase to
promote its replication. In addition, CDK6 is downregulated in
MHV-infected 17Cl1 cells (75). Similar observations have been
made for SARS-CoV, with the N protein limiting cell cycle pro-
gression by reducing CDK4 and CDK6 kinase activity (76). Over-
expression of the SARS-CoV ORF7a protein induced cell cycle
arrest in the G0/G1 phase; however, this was not associated with
inhibition of CDK4 and CDK6 activity (59). In our study, the
antiviral role of CDK6 was confirmed, and the observed antiviral
effect is in line with previous studies.
As pointed out above, our screen yielded a relatively high pro-
portion of antiviral hits, although their effect on SARS-CoV rep-
lication, while being statistically significant, generally was limited.
Based on our assessment of some of these moderate hits, at least
some of themmust have been false positives. Knockdown of PKR
had the strongest effect (2-fold increase in GFP expression) on
SARS-CoV replication, and this hit could be confirmed indepen-
dently, as three out of four individual PKR-directed siRNAs in-
duced a clear increase in SARS-CoV protein expression and virus
yield (Fig. 7C and D). PKR is one of four mammalian kinases that
can phosphorylate eIF-2 in response to stress signals (the others
being the PKR-like endoplasmic reticulumkinase [PERK],GCN2,
and HRI). Many virus families have evolved gene products and
strategies to counteract or evade the antiviral action of PKR, high-
lighting the importance of this kinase in the antiviral defense.
Previously, it was found that PKR inhibits the replication of the
coronavirus IBV, as overexpression of a dominant-negative ki-
nase-defective PKR mutant enhanced IBV replication by almost
2-fold. Furthermore, IBV appeared to (weakly) antagonize the
antiviral activity of PKR through two independent mechanisms,
including a partial block of PKR activation (77). Interestingly,
MHV-A59 infection in L2 or 17Cl1 cells did not induce PKR ac-
tivation, and the sensitivity ofMHV to IFN treatment appeared to
be PKR independent (33, 78, 79). Transmissible gastroenteritis
coronavirus (TGEV) protein 7 was shown to counteract PKR ac-
tivation by binding protein phosphatase 1 to dephosphorylate
eIF-2 (80), which, in support of our findings, also suggests that
PKR is involved in controlling coronavirus replication. Krahling
et al. showed that PKR was activated in SARS-CoV-infected 293/
ACE2 cells but concluded that PKR knockdown did not signifi-
cantly affect virus replication, despite the fact that an 1-log in-
crease in SARS-CoV titer was observed in their experiments (81).
This is in contrast to our PKR knockdown experiments, which
clearly pointed to an antiviral role for PKR (Fig. 8). In our hands,
depletion of PKR significantly increased SARS-CoV-driven GFP
expression (Fig. 8A) and also enhancedN protein expression (Fig.
8C) and the production of infectious progeny (Fig. 8D). This dis-
crepancy cannot be due to host cell differences, as the same 293/
ACE2 cells were used in both studies (81); thus, they might be
attributed to differences in the experimental setup, choice of con-
trols, or normalization and interpretation of the data.
In line with the findings for PKR, reducing the expression of
PERK (or EIF2AK3), one of the other kinases known to phosphor-
ylate eIF-2, resulted in an increase of SARS-CoV-GFP reporter
gene expression to 57% (P 0.01) (see Data Set S1 in the supple-
mental material). The unfolded protein response, i.e., the detec-
tion of misfolded proteins within the ER lumen, activates PERK,
which in turn phosphorylates eIF2 and ultimately triggers apop-
tosis. The relatively strong antiviral effect of PERKobserved in this
study is in linewith previous studies suggesting that the phosphor-
ylation of eIF-2 in SARS-CoV-infected cells ismediated byPERK
activation (81). Our findings support the hypothesis that upon
SARS-CoV infection, the unfolded protein response is activated as
an antiviral strategy. In fact, countering SARS-CoV infectionmay
involve multiple cellular responses that induce apoptosis, includ-
ing the activation of PKR and PERK, which also could explain the
identification of several other hits involved in apoptosis, like those
from the SAPK/JNK pathway.
Among the proviral hits, PRKC had a relatively moderate ef-
fect in the primary screen (Fig. 4B), but its proviral role was vali-
dated using the inhibitor ATM (Fig. 8). Members of the protein
kinase C family are serine/threonine protein kinases and are in-
volved in several signaling pathways that regulate, e.g., cell prolif-
eration, cell cycle progression, and cell survival (reviewed in
reference 82). Interestingly, PRKC can be activated by phospho-
inositol lipids involved in microtubule dynamics within the early
secretory pathway (83). PRKC contains an N-terminal PB1 do-
main that ensures the signaling specificity (reviewed in reference
84), and ATM affects the interaction of PRKC with other PB1
domain-containing proteins, like Par6, MEK5, and p62 (51, 52,
84). Therefore, blocking the PRKC PB1 domain could decrease
MEK5 (85) and NF-B signaling (via p62) and affect cell polarity
(via Par6) (reviewed in reference 84). In addition, PRKC plays an
essential role in COPI vesicle formation, since the GTPase Rab2
binds PRKC and ultimately promotes recruitment of -COP to
pre-Golgi membrane structures for the formation of early secre-
tory vesicles (83, 86, 87). As discussed below, COPB2 and the early
secretory pathway play a crucial role in SARS-CoV replication,
and in this manner PRKC may affect SARS-CoV replication as
well. Tisdale et al. have shown that PRKC kinase activity is essen-
tial for the generation of retrograde transport vesicles (87). How-
ever, the role of the PRKC PB1 domain, the main target of the
drug ATM, in COPI vesicle formation was not directly investi-
gated in this study. Nonetheless, this hypothesis is substantiated
by the ATM concentration that blocked SARS-CoV replication.
Our EC50s are similar to the reported 50% inhibitory concentra-
tion (IC50; 1 M) for inhibition of the PRKC PB-mediated
interactions (51), while the IC50 for inhibition of the kinase activ-
ity was 100-fold higher (88). The exact mechanism by which
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PRKC influences the SARS-CoV replicative cycle remains an in-
teresting topic for future research, and it could even be an inter-
esting target for the development of host-directed antiviral ther-
apy for pathogenic coronaviruses.
Coronavirus replication is associated with a cytoplasmic re-
ticulovesicular network of modified ER, including double-mem-
brane vesicles and convoluted membranes (28). Despite the in-
depth characterization of their ultrastructure, the biogenesis of
these membrane structures and the cellular factors involved have
remained largely uncharacterized. For example, the membrane
source of these coronavirus-induced replication structures still is
controversial, with advanced EM analyses showing the RVN to be
derived from and continuous with the ER (28, 44, 89) and other
studies implicating the autophagy pathway (90) or EDEMosomes
(91) as the primary membrane donor. Our earlier work already
suggested that the integrity of the early secretory pathway is im-
portant for efficient SARS-CoV replication, as brefeldin A treat-
ment of SARS-CoV-infected cells significantly reduced replication
aswell as the accumulation of virus-inducedmembrane structures
(89). In line with these findings, COPI-coated vesicles were impli-
cated in the biogenesis of MHV replication structures (92, 93),
and SARS-CoV nsp3 was shown to interact with three COPI sub-
units (94). In none of these previous SARS-CoV andMHV studies
could a complete block of virus replication be achieved, either by
reducing COPI vesicle formation by depletion of one of the
coatomer subunits or by treatment with brefeldin A. These results
may in part be explained by incomplete knockdown or the pres-
ence of residual COPI vesicles (complete knockdown probably is
not possible due to its detrimental effect on intracellular traffick-
ing and cell viability). Although our present study clearly demon-
strates the importance of COPI vesicles in SARS-CoV replication
(Fig. 9), their role in the formation or function of the SARS-CoV-
induced RVN remains elusive. The importance of COPI-coated
vesicles is further supported by their essential role in the replica-
tion of many other RNA viruses, such as poliovirus (95, 96) and
other picornaviruses (40, 97–100).
In conclusion, our kinome-wide siRNA screen has identified
several cellular proteins and pathways that influence SARS-CoV
replication and possibly coronavirus infections in general. Thus,
our data provide a starting point for further validation and in-
depthmechanistic studies which should enhance our understand-
ing of the complex interplay between coronaviruses and their
host.
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